Disease activity.

This autoimmune disease, chronic inflammation, affects nearly 1 percent of the population and those affected often report ongoing pain despite successful anti-inflammatory treatment. – ‘Since differences in pain sensitivity may be the course of pain complaints and influence treatment decisions influence, it is important to understand the factors sensitivity to pain pain sensitivity,’says lead author Yvonne Lee, study ‘The doctors and researchers should consider both inflammatory and non – inflammatory factors when evaluating pain in research settings and in the clinic. ‘.. Researchers from the Department of Rheumatology and Pain Management Center of Brigham and Women’s Hospital, and the chronic pain and fatigue Center at the University of Michigan Medical School assessed experimental pain sensitivity, disease activity, sleep disorders and psychological distress in 59 women with RA.

Notes: The relationship between disease activity, sleep, psychiatric distress and pain sensitivity in rheumatoid arthritis: a cross-sectional study, Yvonne C. Lee, Lori B Chibnik, Bing Lu, Ajay D Wasan, Robert R Edwards, Anne H Fossel, Simon M Helfgott, Daniel H Solomon.intended This analysis looks, measuring serum HER-2/neu levels, early forecast of the outcome of trastuzumab in MBC patients have have u003c20 percent fall in serum HER-2/neu. A reduced disease free and overall survival rate with trastuzumab-based therapies. Patients with u003c 20 percent for investigative agents should be considered in addition trastuzumab. The serum HER-2/neu Test to a model for the future of personalized medicine into which a serum biomarker the direct of individual therapy will be will constitute, said Allan Lipton, Professor of Medicine and Oncology, Penn State College of Medicine, from Penn State Milton S. HER-2/neu Center and a co-author the pooled analysis of.

The patients who serum HER-2/neu layers declined by is less than 20 per cent had a lower response rate, Collapse durability of the response, a shorter time until progression;. And reduced survival rate.. ‘We are move a new paradigm to to monitor and manage cancer Breast cancer is Dr. ‘out There patients who are achieving excellent results are trastuzumab of treatment and some who do not know with the maximum benefit. It is important for for doctors about the latter group as soon as possible so that you can optimize treatment of regimens. Most common cancer in the world by about 4.4 million breast cancer survivors of to five after diagnosis in the Unites States alone, more than 200,000 women with breast cancer diagnosed annually round 30-50 % of those women to much too much to candidates for HER-2/neu and HER-2/neu a targeted therapy .

Bayer HealthCare, a member of the Bavarian Group announced today announced knowledge from a study with Bayer Diagnostics serum HER-2/neu metastatic breast cancer patients with serum HER-2/neu planes declined experienced differ by less than 20 per cent reduces advantage proven out of trastuzumab therapy.